Ellenbecker Investment Group bought a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 5,767 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.
Several other large investors also recently bought and sold shares of PFE. NuWave Investment Management LLC lifted its position in shares of Pfizer by 439.7% in the 3rd quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,196 shares during the period. Dimension Capital Management LLC purchased a new stake in shares of Pfizer in the 3rd quarter worth about $58,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Pfizer in the 3rd quarter worth about $59,000. Demars Financial Group LLC purchased a new stake in shares of Pfizer in the 2nd quarter worth about $75,000. Finally, RMR Wealth Builders purchased a new stake in shares of Pfizer in the 2nd quarter worth about $91,000. 69.08% of the stock is owned by hedge funds and other institutional investors.
Pfizer stock traded down $0.32 during trading hours on Wednesday, hitting $36.86. The stock had a trading volume of 881,404 shares, compared to its average volume of 36,397,031. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $204.88 billion, a P/E ratio of 14.60, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $43.08. The stock’s 50-day moving average price is $38.24 and its 200-day moving average price is $37.16.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be paid a $0.39 dividend. The ex-dividend date is Thursday, January 28th. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.23%. Pfizer’s payout ratio is currently 51.53%.
PFE has been the subject of several research analyst reports. Royal Bank of Canada set a $42.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, January 4th. JPMorgan Chase & Co. set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, November 9th. Truist initiated coverage on shares of Pfizer in a research report on Friday, October 23rd. They set a “buy” rating and a $42.00 price target for the company. Berenberg Bank initiated coverage on shares of Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price target for the company. Finally, SVB Leerink lifted their price target on shares of Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday, October 28th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $39.87.
In related news, major shareholder Pfizer Inc purchased 1,200,000 shares of Pfizer stock in a transaction dated Tuesday, October 27th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $12,000,000.00. Following the completion of the purchase, the insider now directly owns 27,349,211 shares of the company’s stock, valued at approximately $273,492,110. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.08% of the company’s stock.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Read More: Circuit Breakers
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.